Keymed Biosciences Inc.
Status: Publicly traded
Direct answer
Keymed Biosciences Inc. is publicly traded on HKSE under the ticker 2162.HK.
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic...
Can you invest in Keymed Biosciences Inc.?
Yes. Keymed Biosciences Inc. trades publicly on HKSE as 2162.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Keymed Biosciences Inc.
Detailed equity research is provided by MarketSnap.